- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07647835
3 vs. 5 Days of Amoxicillin for Childhood Pneumonia: An RCT (Pnemonia)
Comparison 0f 03days Vs 05days Amoxicillin In Uncomplicated Community Acquired Pneumonia In Children. A Randomized Controlled Trial
Studieoversigt
Status
Intervention / Behandling
Detaljeret beskrivelse
Pneumonia is the most common infection in children and leading to most common cause of mortality and morbidity in in children globally. Bacterial cause is mostly streptococcus pneumonia in children of 3 months to 5 years of age. Traditionally 7-10 antibiotic is used for uncomplicated community acquired pneumonia. World health organization (WHO) recommends 5 days of antibiotic for non-severe pneumonia with oral amoxicillin while National institute for health and care excellence (NICE) guidelines 2025 recommends 3-days course of amoxicillin in uncomplicated community acquired pneumonia.1,2 Most studies show Short course antibiotic is as effective as long course of antibiotic with fewer side effect. The SAFARI trial demonstrated non-inferiority of 5-day versus 10-day amoxicillin therapy in children with Community acquired pneumonia, with comparable clinical cure rates and reduced antibiotic exposure.3 Similarly, a systematic review and meta-analysis by Pernica et al. found that short-course antibiotic therapy (≤5 days) was associated with similar clinical success rates compared to longer courses in pediatric respiratory infections.4 Mortality due to childhood pneumonia is strongly linked to poverty-related factors such as undernutrition, lack of safe drinking water and sanitation, indoor and outdoor air pollution as well as inadequate access to health care.
Pneumonia kills more children than any other infectious disease, claiming the lives of over 700,000 children under 5 every year, or around 2,000 every day. This includes around 190,000 newborns. Almost all of these deaths are preventable. Globally, there are over 1,400 cases of pneumonia per 100,000 children, or 1 case per 71 children every year, with the greatest incidence occurring in South Asia (2,500 cases per 100,000 children) and West and Central Africa (1,620 cases per 100,000 children).5 No disease kills more children aged less than five years than pneumonia, not least in Pakistan where one-fifth of the population is in this age group. The annual incidence of ARI (acute respiratory infection) in Pakistani children aged less than five years is 4% in the community a group constituting roughly 22% of the country's population of 160 million. Taking this 4% figure, we can calculate that there are 15 million episodes of ARI every year among under-fives.6 The Khyber Pakhtunkhwa province faces particular challenges due to limited healthcare access, malnutrition, and suboptimal vaccination coverage which leads to major burden of pneumonia in less than 5 years' children.7 There is need of local data about effectiveness of short course antibiotic in uncomplicated community acquired pneumonia. 3-day oral amoxicillin has better compliance and less side effect of medicine. Short course of oral amoxicillin is cost effective as pneumonia is more common in low socioeconomic population and 3-day course antibiotic is more economical and has better compliance. Long course of antibiotic leads to antibiotic resistance and adverse effects like diarrhea and other gastrointestinal symptoms.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Tidlig fase 1
Kontakter og lokationer
Studiekontakt
- Navn: Zia Muhammad, MBBS FCPS CHPE CHR PGPN
- Telefonnummer: +923315500086
- E-mail: drziamuhammad@gmail.com
Studiesteder
-
-
Khyber Pakhtunkhwa
-
Peshawar, Khyber Pakhtunkhwa, Pakistan, 25000
- Khyber Teaching Hospital
-
Kontakt:
- Zia Muhammad
- Telefonnummer: 03315500086
- E-mail: drziamuhammad@gmail.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Barn
Tager imod sunde frivillige
Beskrivelse
Inclusion criteria:
- Age; ≥ 3 months to 5 years
- Fever; recorded temperature of ≥100.4 f or guardian reported fever within 2 days
- Cough; observed or reported within 3 days
- Tachypnea;
- 3 months to 1 years ≥ 50 breaths per minute
- 1 years to 5 years ≥ 40 breaths per minute
- C- reactive protein ≥ 40
- White blood cells ≥ 12200
- Chest X-ray;
- Presence of a dense opacity occupying a portion or whole of lobe with or without air Broncho grams.
Exclusion criteria:
- Patient who is Lethargic and unable to tolerate orally.
- Capillary refill greater than 2 second
- Chronic lung disease
- Congenital heart disease or sickle cell anemia patient
- Immunocompromised patient
- malnourished
- Known or suspected tuberculosis patient
- Patient has used prior antibiotic within 2 days
- Allergic to penicillin or amoxicillin
- C-reactive protein greater than 72
- White blood cells greater than 25000
- Chest x rays show linear or patchy or peri bronchial opacity
- Presence of pleural effusions
- Empyema, lung abscess, necrotizing pneumonia or pneumatocele
- Other alternative diagnosis like wheezing syndrome (Bilateral wheezing on auscultation)
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: - Group B (5-day): Amoxicillin suspension 80-90 mg/kg/day divided twice daily for 5 days.
|
Giving drug for 3 days instead of 5 days
|
|
Eksperimentel: Group A (3-day): Amoxicillin suspension 80-90 mg/kg/day divided twice daily for 3 days
Group A (3-day): Amoxicillin suspension 80-90 mg/kg/day divided twice daily for 3 days, followed by matched placebo for days 4-5
|
Giving drug for 3 days instead of 5 days
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Participants with Clinical Cure at Day 14
Tidsramme: 14 days
|
Participants who
|
14 days
|
|
Number of Participants withTreatment Failure:
Tidsramme: 5 days
|
Participants who
|
5 days
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Luftvejsinfektioner
- Infektioner
- Luftvejssygdomme
- Lungebetændelse
- Samfundserhvervede infektioner
- Samfundserhvervet lungebetændelse
- Svovlforbindelser
- Organiske kemikalier
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ring
- Amider
- Penicillin g
- beta-lactams
- Lactams
- Ampicillin
- Penicillins
- Amoxicillin
Andre undersøgelses-id-numre
- 318/IREB/KTH
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Samfundserhvervet lungebetændelse
-
Capital Medical UniversityChina-Japan Friendship Hospital; Beijing Municipal Health CommissionIkke rekrutterer endnuCommunity Acquired Pneumonia (CAP)Kina
-
University of Maryland, BaltimoreIkke rekrutterer endnuCommunity Acquired Pneumonia (CAP)Forenede Stater
-
Sohag UniversityIkke rekrutterer endnuCommunity Acquired Pneumonia (CAP)
-
Ann & Robert H Lurie Children's Hospital of ChicagoPatient-Centered Outcomes Research InstituteRekrutteringSamfundserhvervet lungebetændelse | Community Acquired Pneumonia (CAP)Forenede Stater
-
PfizerAfsluttetCommunity Acquired Pneumonia (CAP)Spanien
-
PfizerAfsluttetCommunity Acquired Pneumonia (CAP)Japan
-
Children's Hospital of PhiladelphiaPatient-Centered Outcomes Research InstituteAktiv, ikke rekrutterendeBihulebetændelse | Community Acquired Pneumonia (CAP) | Akut mellemørebetændelse (AOM) | Strep PharyngitisForenede Stater
-
Copenhagen Respiratory ResearchIkke rekrutterer endnuCommunity Acquired Pneumonia (CAP)
-
Copenhagen Respiratory ResearchRekrutteringCommunity Acquired Pneumonia (CAP)Danmark
-
Societa Italiana di PneumologiaRekrutteringCommunity Acquired Pneumonia (CAP)Italien
Kliniske forsøg med Amoxicillin
-
Universita degli Studi di GenovaIkke rekrutterer endnu
-
Saskatchewan Health Authority - Regina AreaIkke rekrutterer endnu
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityAfsluttetUdryddelseshastighed for Helicobacter PyloriKina
-
University of Alabama at BirminghamMerck Sharp & Dohme LLCAfsluttetPostpartum sepsis | Postpartum Endometritis | Postpartum feberCameroun
-
Malmö UniversityAfsluttetAntibiotisk profylakse | InfektionskontrolSverige
-
Yanqing LiQilu Hospital of Shandong University; Shandong University of Traditional... og andre samarbejdspartnereRekruttering
-
Yueyue LiQilu Hospital of Shandong University; Shandong University of Traditional... og andre samarbejdspartnereIkke rekrutterer endnu
-
Second Affiliated Hospital, School of Medicine,...Ikke rekrutterer endnuHELICOBACTER PYLORI INFEKTIONER
-
ARI Research CellWorld Health OrganizationAfsluttet
-
Boston Medical CenterWorld Health OrganizationAfsluttet